Natural Killer Cells to the Attack: Combination Therapy against Neuroblastoma

被引：10

作者：

Zenarruzabeitia, Olatz ^{[1
]}

Vitalle, Joana ^{[1
]}

Astigarraga, Itziar ^{[2
,3
,4
]}

Borrego, Francisco ^{[1
,5
,6
]}

机构：

[1] BioCruces Hlth Res Inst, Immunopathol Grp, Baracaldo, Spain

[2] BioCruces Hlth Res Inst, Pediat Oncol Grp, Baracaldo, Spain

[3] Cruces Univ Hosp, Serv Pediat, Baracaldo, Spain

[4] Univ Basque Country, Fac Med & Dent, Dept Pediat, Leioa, Spain

[5] Ctr Transfus & Human Tissues, Immunotherapy Grp, Galdakao, Spain

[6] Basque Fdn Sci, Ikerbasque, Bilbao, Spain

来源：

CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 03期

关键词：

ANTI-GD2; ANTIBODY; CANCER; DINUTUXIMAB;

D O I：

10.1158/1078-0432.CCR-16-2478

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TGF beta in the tumor microenvironment diminishes natural killer (NK) cell-mediated anti-disialoganglioside (anti-GD2) mAb elimination of neuroblastoma cells. Consequently, blockade of TGFb signaling with galunisertib in combination with the anti-GD2 mAb dinutuximab plus adoptively transferred NK cells is a promising tool for the treatment of neuroblastoma. (C) 2016 AACR.

引用

页码：615 / 617

页数：3

共 12 条

[1] Editorial: NK Cell-Based Cancer immunotherapy
Borrego, Francisco
Larrucea, Susana
Solana, Rafael
Tarazona, Raquel
[J]. FRONTIERS IN IMMUNOLOGY, 2016, 7
[2] Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches
Bottino, Cristina
Dondero, Alessandra
Bellora, Francesca
Morette, Lorenzo
Locatelli, Franco
Pistoia, Vito
Moretta, Alessandro
Castriconi, Roberta
[J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
[3] TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells
Donatelli, Sarah S.
Zhou, Jun-Min
Gilvary, Danielle L.
Eksioglu, Erika A.
Chen, Xianghong
Cress, W. Douglas
Haura, Eric B.
Schabath, Matthew B.
Coppola, Domenico
Wei, Sheng
Djeu, Julie Y.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (11) : 4203 - 4208
[4] Targeting natural killer cells in cancer immunotherapy
Guillerey, Camille
Huntington, Nicholas D.
Smyth, Mark J.
[J]. NATURE IMMUNOLOGY, 2016, 17 (09) : 1025 - 1036
[5] Neuroblastoma
Maris, John M.
Hogarty, Michael D.
Bagatell, Rochelle
Cohn, Susan L.
[J]. LANCET, 2007, 369 (9579) : 2106 - 2120
[6] Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
Mora, Jaume
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 647 - 653
[7] Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1
Park, Yuk Pheel
Choi, Seung-Chul
Kiesler, Patricia
Gil-Krzewska, Aleksandra
Borrego, Francisco
Weck, Jennifer
Krzewski, Konrad
Coligan, John E.
[J]. BLOOD, 2011, 118 (11) : 3019 - 3027
[8] First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Rodon, Jordi
Carducci, Michael A.
Sepulveda-Sanchez, Juan M.
Azaro, Analia
Calvo, Emiliano
Seoane, Joan
Brana, Irene
Sicart, Elisabet
Gueorguieva, Ivelina
Cleverly, Ann L.
Pillay, N. Sokalingum
Desaiah, Durisala
Estrem, Shawn T.
Paz-Ares, Luis
Holdhoff, Matthias
Blakeley, Jaishri
Lahn, Michael M.
Baselga, Jose
[J]. CLINICAL CANCER RESEARCH, 2015, 21 (03) : 553 - 560
[9] Natural killer cell mediated immunosurveillance of pediatric neuroblastoma
Semeraro, Michaela
Rusakiewicz, Sylvie
Zitvogel, Laurence
Kroemer, Guido
[J]. ONCOIMMUNOLOGY, 2015, 4 (11):
[10] TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Tran, Hung C.
Wan, Zesheng
Sheard, Michael A.
Sun, Jianping
Jackson, Jeremy R.
Malvar, Jemily
Xu, Yibing
Wang, Larry
Sposto, Richard
Kim, Eugene S.
Asgharzadeh, Shahab
Seeger, Robert C.
[J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 804 - 813

← 1 2 →